{
 "note": "Landmark GLP-1 / dual-agonist trials for approved products. Headline results are well-established from published reports. NCT identifiers are included only where high-confidence; entries marked verify_id require final citation-audit confirmation of NCT/DOI/PMID before any research page citing them is indexed. Compounded and microdose products are NOT represented by these trials.",
 "captured": "2026-07-20",
 "studies": [
  {
   "id": "step1",
   "name": "STEP 1",
   "drug": "semaglutide 2.4 mg (weekly SC)",
   "population": "Adults with overweight/obesity, without diabetes",
   "design": "RCT, 68 weeks, placebo-controlled",
   "n": 1961,
   "result_pct": 14.9,
   "result": "Mean weight change about -14.9% vs -2.4% placebo",
   "journal": "N Engl J Med",
   "year": 2021,
   "nct": "NCT03548935",
   "id_status": "verified",
   "doi": "10.1056/NEJMoa2032183",
   "pmid": "33567185",
   "citation": "Wilding JPH, et al. N Engl J Med 2021;384:989-1002",
   "source": "https://clinicaltrials.gov/study/NCT03548935",
   "pubmed": "https://pubmed.ncbi.nlm.nih.gov/33567185/",
   "doi_url": "https://doi.org/10.1056/NEJMoa2032183"
  },
  {
   "id": "step3",
   "name": "STEP 3",
   "drug": "semaglutide 2.4 mg + intensive behavioral therapy",
   "population": "Adults with overweight/obesity",
   "design": "RCT, 68 weeks",
   "n": 611,
   "result_pct": 16.0,
   "result": "About -16.0% with drug + IBT vs -5.7% placebo + IBT",
   "journal": "JAMA",
   "year": 2021,
   "nct": "NCT03611582",
   "id_status": "verified",
   "doi": "10.1001/jama.2021.1831",
   "pmid": "33625476",
   "citation": "Wadden TA, et al. JAMA 2021;325(14):1403-1413",
   "source": "https://clinicaltrials.gov/study/NCT03611582",
   "pubmed": "https://pubmed.ncbi.nlm.nih.gov/33625476/",
   "doi_url": "https://doi.org/10.1001/jama.2021.1831"
  },
  {
   "id": "step4",
   "name": "STEP 4",
   "drug": "semaglutide 2.4 mg (continuation vs withdrawal)",
   "population": "Adults with overweight/obesity after 20-week run-in",
   "design": "RCT withdrawal design, to week 68",
   "n": 803,
   "result_pct": null,
   "result": "Continuing lost further weight; switching to placebo regained substantial weight",
   "journal": "JAMA",
   "year": 2021,
   "nct": "NCT03548987",
   "id_status": "verified",
   "doi": "10.1001/jama.2021.3224",
   "pmid": "33755728",
   "citation": "Rubino D, et al. JAMA 2021;325(14):1414-1425",
   "source": "https://clinicaltrials.gov/study/NCT03548987",
   "pubmed": "https://pubmed.ncbi.nlm.nih.gov/33755728/",
   "doi_url": "https://doi.org/10.1001/jama.2021.3224"
  },
  {
   "id": "surmount1",
   "name": "SURMOUNT-1",
   "drug": "tirzepatide (5/10/15 mg weekly SC)",
   "population": "Adults with obesity, without diabetes",
   "design": "RCT, 72 weeks, placebo-controlled",
   "n": 2539,
   "result_pct": 20.9,
   "result": "Up to about -20.9% at 15 mg vs -3.1% placebo",
   "journal": "N Engl J Med",
   "year": 2022,
   "nct": "NCT04184622",
   "id_status": "verified",
   "doi": "10.1056/NEJMoa2206038",
   "pmid": "35658024",
   "citation": "Jastreboff AM, et al. N Engl J Med 2022;387(3):205-216",
   "source": "https://clinicaltrials.gov/study/NCT04184622",
   "pubmed": "https://pubmed.ncbi.nlm.nih.gov/35658024/",
   "doi_url": "https://doi.org/10.1056/NEJMoa2206038"
  },
  {
   "id": "surmount2",
   "name": "SURMOUNT-2",
   "drug": "tirzepatide (10/15 mg)",
   "population": "Adults with obesity and type 2 diabetes",
   "design": "RCT, 72 weeks",
   "n": 938,
   "result_pct": 14.7,
   "result": "About -12.8% to -14.7% vs -3.2% placebo",
   "journal": "Lancet",
   "year": 2023,
   "nct": "NCT04657003",
   "id_status": "verified",
   "doi": "10.1016/S0140-6736(23)01200-X",
   "pmid": "37385274",
   "citation": "Garvey WT, et al. Lancet 2023;402(10402):613-626",
   "source": "https://clinicaltrials.gov/study/NCT04657003",
   "pubmed": "https://pubmed.ncbi.nlm.nih.gov/37385274/",
   "doi_url": "https://doi.org/10.1016/S0140-6736(23)01200-X"
  },
  {
   "id": "surmount4",
   "name": "SURMOUNT-4",
   "drug": "tirzepatide (maintenance vs withdrawal)",
   "population": "Adults with obesity after lead-in",
   "design": "RCT withdrawal design",
   "n": 670,
   "result_pct": null,
   "result": "Continued treatment maintained loss; withdrawal led to regain",
   "journal": "JAMA",
   "year": 2024,
   "nct": "NCT04660643",
   "id_status": "verified",
   "doi": "10.1001/jama.2023.24945",
   "pmid": "38078870",
   "citation": "Aronne LJ, et al. JAMA 2024;331(1):38-48",
   "source": "https://clinicaltrials.gov/study/NCT04660643",
   "pubmed": "https://pubmed.ncbi.nlm.nih.gov/38078870/",
   "doi_url": "https://doi.org/10.1001/jama.2023.24945"
  },
  {
   "id": "select",
   "name": "SELECT",
   "drug": "semaglutide 2.4 mg",
   "population": "Adults with CVD and overweight/obesity, without diabetes",
   "design": "RCT, CV outcomes",
   "n": 17604,
   "result_pct": null,
   "result": "About 20% reduction in major adverse cardiovascular events",
   "journal": "N Engl J Med",
   "year": 2023,
   "nct": "NCT03574597",
   "id_status": "verified",
   "doi": "10.1056/NEJMoa2307563",
   "pmid": "37952131",
   "citation": "Lincoff AM, et al. N Engl J Med 2023;389:2221-2232",
   "source": "https://clinicaltrials.gov/study/NCT03574597",
   "pubmed": "https://pubmed.ncbi.nlm.nih.gov/37952131/",
   "doi_url": "https://doi.org/10.1056/NEJMoa2307563"
  },
  {
   "id": "sustain6",
   "name": "SUSTAIN-6",
   "drug": "semaglutide (weekly SC)",
   "population": "Adults with type 2 diabetes at high CV risk",
   "design": "RCT, CV outcomes",
   "n": 3297,
   "result_pct": null,
   "result": "Reduced CV events vs placebo in type 2 diabetes",
   "journal": "N Engl J Med",
   "year": 2016,
   "nct": "NCT01720446",
   "id_status": "verified",
   "doi": "10.1056/NEJMoa1607141",
   "pmid": "27633186",
   "citation": "Marso SP, et al. N Engl J Med 2016;375(19):1834-1844",
   "source": "https://clinicaltrials.gov/study/NCT01720446",
   "pubmed": "https://pubmed.ncbi.nlm.nih.gov/27633186/",
   "doi_url": "https://doi.org/10.1056/NEJMoa1607141"
  },
  {
   "id": "oasis1",
   "name": "OASIS 1",
   "drug": "oral semaglutide 50 mg",
   "population": "Adults with overweight/obesity, without diabetes",
   "design": "RCT, 68 weeks",
   "n": 667,
   "result_pct": 15.1,
   "result": "About -15.1% vs -2.4% placebo with the approved oral formulation",
   "journal": "Lancet",
   "year": 2023,
   "nct": "NCT05035095",
   "id_status": "verified",
   "doi": "10.1016/S0140-6736(23)01185-6",
   "pmid": "37385278",
   "citation": "Knop FK, et al. Lancet 2023;402(10403):705-719",
   "source": "https://clinicaltrials.gov/study/NCT05035095",
   "pubmed": "https://pubmed.ncbi.nlm.nih.gov/37385278/",
   "doi_url": "https://doi.org/10.1016/S0140-6736(23)01185-6"
  }
 ],
 "identifier_verification": "NCT numbers verified against ClinicalTrials.gov; DOIs and PMIDs verified against PubMed/journal records, 2026-07-20",
 "verified_count": 9
}